Tara Davis

Dr. Tara Davis


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2010 in PLOS Biology
Verified
Journal Article
Open access
PDF file
TDTara Davis
Tara Davis
JWJohn R. Walker
John R. Walker
VCValérie Campagna-Slater
Valérie Campagna-Slater
PFPatrick J. Finerty
Patrick J. Finerty
RPRagika Paramanathan
Ragika Paramanathan
SDSirano Dhe-Paganon
Sirano Dhe-Paganon
Peptidyl-prolyl isomerases catalyze the conversion between cis and trans isomers of proline. The cyclophilin family of peptidyl-prolyl isomerases is well known for being the target of the immunosuppressive drug cyclosporin, used to combat organ transplant rejection. There is great interest in both the substrate specificity of these enzymes and the design of isoform-selective ligands for them. However, the dearth of available data for individual family members inhibits attempts to design drug specificity; additionally, in order to define physiological functions for the cyclophilins, definitive isoform characterization is required. In the current study, enzymatic activity was assayed for 15 of the 17 human cyclophilin isomerase domains, and binding to the cyclosporin scaffold was tested. In order to rationalize the observed isoform diversity, the high-resolution crystallographic structures of seven cyclophilin domains were determined. These models, combined with seven previously solved cyclophilin isoforms, provide the basis for a family-wide structure∶function analysis. Detailed structural analysis of the human cyclophilin isomerase explains why cyclophilin activity against short peptides is correlated with an ability to ligate cyclosporin and why certain isoforms are not competent for either activity. In addition, we find that regions of the isomerase domain outside the proline-binding surface impart isoform specificity for both in vivo substrates and drug design. We hypothesize that there is a well-defined molecular surface corresponding to the substrate-binding S2 position that is a site of diversity in the cyclophilin family. Computational simulations of substrate binding in this region support our observations. Our data indicate that unique isoform determinants exist that may be exploited for development of selective ligands and suggest that the currently available small-molecule and peptide-based ligands for this class of enzyme are insufficient for isoform specificity. This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3-D representations and animated transitions. Please note that a Web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1. Cyclophilins are proteins that catalyze the isomerization of prolines, interconverting this structurally important amino acid between cis and trans isomers. Although there are 17 cyclophilins in the human genome, the function of most cyclophilin isoforms is unknown. At least some members of this protein family are of interest for clinically relevant drug design, as they are targets of the drug cyclosporin, which is used as an immunosuppressant to treat patients following organ transplantation. The absence of a comprehensive picture of the similarities and differences between the different members of this protein family precludes effective and specific drug design, however. In the current study we undertake such a global structure∶function analysis. Using biochemical, structural, and computational methods we characterize the human cyclophilin family in detail and suggest that there is a previously overlooked region of these enzymes that contributes significantly to isoform diversity. We propose that this region may represent an important target for isoform-specific drug design.

15 August 2008 in Biochemistry
Verified
Journal Article
Closed access
CECécilia Eydoux
Cécilia Eydoux
SSSilvia Spinelli
Silvia Spinelli
TDTara Davis
Tara Davis
JWJohn R. Walker
John R. Walker
ASAlma Seitova
Alma Seitova
FCFrédéric Carriere
Frédéric Carriere

1 May 2017 in Molecular Cell
Verified
Journal Article
Closed access
CGChelsea L. Gustafson
Chelsea L. Gustafson
NPNicole C. Parsley
Nicole C. Parsley
HAHande Asimgil
Hande Asimgil
HLHsiau-Wei Lee
Hsiau-Wei Lee
CAChristopher Ahlbach
Christopher Ahlbach
CPCarrie L. Partch
Carrie L. Partch

1 June 2008 in Structure
Verified
Journal Article
Closed access
TDTara Davis
Tara Davis
JWJohn R. Walker
John R. Walker
PLPeter Loppnau
Peter Loppnau
CBChristine Butler-Cole
Christine Butler-Cole
AAAbdellah Allali-Hassani
Abdellah Allali-Hassani
SDSirano Dhe-Paganon
Sirano Dhe-Paganon

16 July 2005 in Biochemistry
Verified
Journal Article
Closed access
TDTara Davis
Tara Davis
TBTabetha M. Bonacci
Tabetha M. Bonacci
SSStephen R. Sprang
Stephen R. Sprang
ASAlan V. Smrcka
Alan V. Smrcka

1 February 2007 in Journal of Molecular Biology
Verified
Journal Article
Closed access
TDTara Davis
Tara Davis
JWJohn R. Walker
John R. Walker
PFPatrick J. Finerty
Patrick J. Finerty
FMFarrell Mackenzie
Farrell Mackenzie
ENElena M. Newman
Elena M. Newman
SDSirano Dhe-Paganon
Sirano Dhe-Paganon